Content about WHITEHOUSE STATION

October 6, 2011

Merck chairman Richard Clark is retiring, the company said Thursday.

WHITEHOUSE STATION, N.J. — Merck chairman Richard Clark is retiring, the company said Thursday.

Merck announced that Clark, who remained chairman of the company after stepping down as president and CEO in 2010, would retire from the company and its board of directors as of Dec. 1. Kenneth Frazier took over as president and CEO in January 2011, and the board has elected him to serve as chairman following Clark's departure.

October 5, 2011

The Food and Drug Administration has accepted a regulatory approval application from Merck and Ariad Pharmaceuticals for a new drug to treat soft-tissue and bone cancers, the drug makers said Wednesday.

WHITEHOUSE STATION, N.J. — The Food and Drug Administration has accepted a regulatory approval application from Merck and Ariad Pharmaceuticals for a new drug to treat soft-tissue and bone cancers, the drug makers said Wednesday.

The FDA is expected to complete its review of ridaforolimus for soft-tissue and bone sarcomas in patients who have shown a favorable response to chemotherapy by second quarter 2012.

Sarcomas are cancers of the body's connective tissues, and treatment options remain limited, the companies said.

July 29, 2011

Merck disclosed plans to reduce its workforce by 12% to 13% by the end of 2015, the company announced Friday in its second-quarter earnings release.

WHITEHOUSE STATION, N.J. — Merck disclosed plans to reduce its workforce by 12% to 13% by the end of 2015, the company announced Friday in its second-quarter earnings release.

July 14, 2011

A team comprised of scientists from drug maker Merck and several U.S. universities will look for ways to eradicate HIV, Merck said.

WHITEHOUSE STATION, N.J. — A team comprised of scientists from drug maker Merck and several U.S. universities will look for ways to eradicate HIV, Merck said.

June 13, 2011

Merck will collaborate with a Korean manufacturer to develop a biosimilar version of a drug used for autoimmune diseases.

WHITEHOUSE STATION, N.J. — Merck will collaborate with a Korean manufacturer to develop a biosimilar version of a drug used for autoimmune diseases.

Merck, which operates outside the United States and Canada as MSD to avoid confusion with Germany-based Merck KGaA, announced Monday a collaboration with Seoul, South Korea-based Hanwha Chemical to develop and commercialize HD203, a biosimilar version of Enbrel (etanercept), made by Amgen and Pfizer. The drug is used to treat such disorders as rheumatoid arthritis and psoriasis.

May 16, 2011

Drug maker Merck has completed its acquisition of eye care company Inspire.

WHITEHOUSE STATION, N.J. — Drug maker Merck has completed its acquisition of eye care company Inspire.

As previously reported, Merck announced its plan to acquire the company for $5 per share in cash, or $430 million. In addition, Monarch Transaction, a wholly-owned subsidiary of Merck, has merged with and into Inspire, with Inspire surviving as a wholly owned subsidiary of Merck, effective today.

May 9, 2011

Drug maker Merck announced that it has kicked off an initiative that includes a wide range of public education and patient support programs, as well as research efforts to help improve care for people living with chronic hepatitis C virus infections.

WHITEHOUSE STATION, N.J. — Drug maker Merck announced that it has kicked off an initiative that includes a wide range of public education and patient support programs, as well as research efforts to help improve care for people living with chronic hepatitis C virus infections.

Merck's Hope Against Hepatitis C initiative includes a variety of public-private partnerships, educational programs and collaborative research efforts aimed at supporting the hepatitis C community.

April 28, 2011

Merck has cleared a hurdle in its effort to buy eye care company Inspire Pharmaceuticals for $430 million, the company said Thursday.

WHITEHOUSE STATION, N.J. — Merck has cleared a hurdle in its effort to buy eye care company Inspire Pharmaceuticals for $430 million, the company said Thursday.

The expiration of the waiting period mandated by the Hart-Scott-Rodino Antitrust Improvements Act of 1976 brings Merck one step closer to acquiring Inspire.

Merck announced its intention to buy Raleigh, N.C.-based Inspire for $5 per share on April 15.

April 21, 2011

Merck and Sanofi Pasteur have started a late-stage clinical trial of a combination vaccine for six childhood diseases, the companies said Thursday.

WHITEHOUSE STATION, N.J. — Merck and Sanofi Pasteur have started a late-stage clinical trial of a combination vaccine for six childhood diseases, the companies said Thursday.

April 12, 2011

The Food and Drug Administration has approved a treatment made by Merck for treating skin cancer, Merck said Monday.

WHITEHOUSE STATION, N.J. — The Food and Drug Administration has approved a treatment made by Merck for treating skin cancer, Merck said Monday.

Merck announced the approval of Sylatron (peginterferon alfa-2b) as an add-on treatment for treating melanoma with microscopic of gross nodal involvement within 84 days of surgery.

April 5, 2011

Drug maker Merck is looking to boost its eye care portfolio by acquiring a company focused on developing and commercializing ophthalmic products. The deal carries a cash value of about $430 million.

WHITEHOUSE STATION, N.J. — Drug maker Merck is looking to boost its eye care portfolio by acquiring a company focused on developing and commercializing ophthalmic products. The deal carries a cash value of about $430 million.

March 9, 2011

The Food and Drug Administration has accepted an approval application from Merck for a drug to treat eye diseases, Merck said Wednesday.

WHITEHOUSE STATION, N.J. — The Food and Drug Administration has accepted an approval application from Merck for a drug to treat eye diseases, Merck said Wednesday.

Merck is seeking approval for Saflutan (tafluprost) ophthalmic solution, an investigational drug for relieving eye pressure in patients with glaucoma and ocular hypertension.

February 4, 2011

Coppertone, which is made by Merck's Consumer Care division, is gearing up for summer with its new foaming lotion sunscreens.

WHITEHOUSE STATION, N.J. — Coppertone, which is made by Merck's Consumer Care division, is gearing up for summer with its new foaming lotion sunscreens.

"Our breakthrough foaming lotion technology offered the opportunity to reinvent our Water Babies and Oil Free products," stated Patricia Agin, fellow in skin care research and development at the Solar Research Center. "We continuously innovate to meet consumers' evolving needs for gentle protection in easy-to-use formulas."

The new products for 2011 include:

February 3, 2011

Merck’s vaccine for human papillomavirus is 89% effective in preventing genital warts in teenage boys and young men, according to a new study.

WHITEHOUSE STATION, N.J. — Merck’s vaccine for human papillomavirus is 89% effective in preventing genital warts in teenage boys and young men, according to a new study.

The phase-3 study of Gardasil (human papillomavirus quadrivalent [types 6, 11, 16 and 18] vaccine, recombinant) in boys and men ages 16 to 26 years was published in the Feb. 3 issue of the New England Journal of Medicine. Human papillomavirus is the cause of genital and anal warts, and infection can increase the risk of developing cancer later in life.

January 12, 2011

Drug maker Merck and drug industry services organization Parexel International will work together to develop biosimilars, the two said Wednesday.

WHITEHOUSE STATION, N.J. — Drug maker Merck and drug industry services organization Parexel International will work together to develop biosimilars, the two said Wednesday.

Under the agreement, Parexel will give Merck BioVentures access to clinical and regulatory services for the development of biosimilars. Financial terms of the agreement were not disclosed.

January 11, 2011

The Food and Drug Administration has accepted a regulatory approval application for a drug to treat Type 2 diabetes made by Merck, the drug maker said Tuesday.

WHITEHOUSE STATION, N.J. — The Food and Drug Administration has accepted a regulatory approval application for a drug to treat Type 2 diabetes made by Merck, the drug maker said Tuesday.

Merck announced the acceptance of its application for extended-release Janumet, which combines in a single pill the active ingredient sitagliptin with extended-release metformin, a drug commonly prescribed for Type 2 diabetes.

January 6, 2011

The Food and Drug Administration granted priority review to an approval application for a hepatitis C drug made by Merck, the drug maker said Thursday.

WHITEHOUSE STATION, N.J. — The Food and Drug Administration granted priority review to an approval application for a hepatitis C drug made by Merck, the drug maker said Thursday.

Merck said the FDA would seek to complete its review of the application for the drug boceprevir within six months. Authorities in the European Union have granted expedited review as well.

December 23, 2010

Merck on Wednesday announced that the Food and Drug Administration has approved Gardasil [human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant] for the prevention of anal cancer in males and females 9 to 26 years of age.

WHITEHOUSE STATION, N.J. — Merck on Wednesday announced that the Food and Drug Administration has approved Gardasil [human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant] for the prevention of anal cancer in males and females 9 to 26 years of age.

According to the company, Gardasil is the first HPV vaccine on the market available for use in both men and women, and the only one indicated  to help prevent cervical, vaginal, vulvar and anal cancers and pre-cancers, as well as genital warts, caused by certain types of HPV.

December 2, 2010

Merck announced on Thursday it has inked a deal to acquire an insulin maker.

WHITEHOUSE STATION, N.J., and BEVERLY, Mass. (Dec. 2) Merck announced on Thursday it has inked a deal to acquire an insulin maker.

November 30, 2010

The president of drug maker Merck now will fill an additional position at the company: CEO.

WHITEHOUSE STATION, N.J. — The president of drug maker Merck now will fill an additional position at the company: CEO.

Merck's board of directors elected president and board member Kenneth Frazier as the company's next leader, effective Jan. 1. Frazier will succeed Richard Clark, who has served as Merck's CEO since 2005. Clark will continue as chairman of the board, the drug maker said.

November 16, 2010

A Food and Drug Administration advisory committee has recommended expanded approval of a vaccine for...

WHITEHOUSE STATION, N.J. — A Food and Drug Administration advisory committee has recommended expanded approval of a vaccine for genital warts.

Merck announced Wednesday that the FDA Vaccines and Related Biological Products Advisory Committee recommended approval of Gardasil (human papillomavirus quadrivalent [types 6, 11, 16 and 18] vaccine, recombinant) for males and females ages 9 to 26 years to prevent anal cancer and anal intraepithelial neoplasia, both diseases that result from infection by the human papillomavirus.

November 16, 2010

Patients taking an investigational treatment for cardiovascular disease showed big improvements in cholesterol levels, according...

WHITEHOUSE STATION, N.J. Patients taking an investigational treatment for cardiovascular disease showed big improvements in cholesterol levels, according to late-stage clinical trial results released Wednesday.

 

September 21, 2010

Merck is expanding its patient assistance program, the drug maker said Wednesday....

WHITEHOUSE STATION, N.J. Merck is expanding its patient assistance program, the drug maker said Wednesday.

September 8, 2010

Merck's supplemental drug applications for its atypical antipsychotic received approval from the Food and Drug...

WHITEHOUSE STATION, N.J. Merck's supplemental drug applications for its atypical antipsychotic received approval from the Food and Drug Administration, the drug maker said.

Saphris now is indicated for the treatment of schizophrenia in adults, as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, and as adjunctive therapy with either lithium or valproate for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, Merck said.

August 23, 2010

Merck Consumer Care on Tuesday announced the launch of Dr. Scholl's For Her Fast Flats,...